Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.

Name: Kaimen Rigor review — A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.
Item: A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.
Rating: 96
Author: Alpha1

Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, Chisele S, Shibemba AL, Sauvaget C, Sankaranarayanan R, Prendiville W, Parham GP

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.

Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, Chisele S, Shibemba AL, Sauvaget C, Sankaranarayanan R, Prendiville W, Parham GP

Read full text (PMC)

DOI

10.1038/s41591-024-03080-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0e7f1368-4384-435f-83d7-3d25617699f4" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0e7f1368-4384-435f-83d7-3d25617699f4/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a55430236b9b276b858a3e50dbe39504e035af98ed4fe16eb37bdd9fae1aabf2

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.

Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, Chisele S, Shibemba AL, Sauvaget C, Sankaranarayanan R, Prendiville W, Parham GP

Paper source

A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is treatment success defined as type-specific HPV clearance or negative VIA, which are surrogate markers for cervical precancer resolution. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD) and does not cite validated evidence linking these surrogates to clinical outcomes such as prevention of cervical cancer. Although the discussion mentions HPV clearance as a 'test of cure' with high negative predictive value, this is not a validated surrogate for the clinical outcome of cervical cancer prevention.
“The primary outcome was treatment success, defined as either type-specific HPV clearance at the follow-up in participants positive for HPV at baseline, or a negative visual inspection with acetic acid test for those who had a negative HPV test at baseline.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The treatment success rates are around 71-74% overall, and among HPV-positive women, type-specific clearance is only about 50%. These are not anchored to a minimal clinically important difference or to the clinical significance for preventing cervical cancer. The paper does not provide a benchmark for what constitutes a clinically meaningful success rate, and the rates are lower than those reported in meta-analyses using histopathological endpoints.
“After a median follow-up of 12 months, treatment success rates were 74.0%, 71.1% and 71.4% for the TA, cryotherapy and LLETZ arms, respectively, thus demonstrating noninferiority ( P = 0.83).”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit9 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized noninferiority trial with strong methodology across most dimensions. The main weakness is the vague data and code availability statements, which lack a concrete repository or managed-access platform. Minor copyediting issues in Table 5 (point estimates inconsistent with confidence intervals) warrant correction.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence to reconcile. The statistics verification component recomputed only 2 tests (1 consistent, 0 inconsistent) due to limited coverage; most reported statistics remain unverified. The citation check found no retracted or unresolved references. The reproducibility check confirmed the one link is live.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites WHO guidelines and prior studies on cryotherapy and LLETZ, acknowledges the lack of RCT evidence for TA, and explains the need for the trial. The rationale links the evidence gap to the study objectives, and the limitations of prior research (e.g., conditional WHO recommendation based on low certainty) are explicitly addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise, citing prior work and guidelines, and provides a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 1]

“The ‘screen-and-treat’ approach... is a well-accepted protocol in cervical screening programs in low- and middle-income countries (LMICs). The strategy has been endorsed in the latest guideline published by the World Health Organization (WHO) in 2021”

paraphrase[Introduction, paragraph 3]

“Despite these advantages, the 2019 WHO recommendation was ‘conditional’ and based on ‘very low certainty in evidence of effects’ given the lack of evidence from any randomized controlled trial (RCT) directly comparing the two treatment strategies in screen-and-treat settings.”

paraphrase[Discussion, paragraph 4]

“In their meta-analysis of 13 studies evaluating TA, Dolman et al. reported a high cure rate of 95%... None had any data on women who were HIV positive. The results from our large prospective RCT provide much needed evidence on the noninferiority of efficacy of TA compared to cryotherapy or LLETZ”

PASSReviewer 2· 90% conf

The study clearly establishes the scientific premise, citing prior work and guidelines, and provides a logical rationale for the trial.

Evidence

paraphrase[Main, paragraph 1]

“the 2019 WHO recommendation was ‘conditional’ and based on ‘very low certainty in evidence of effects’ given the lack of evidence from any randomized controlled trial (RCT) directly comparing the two treatment strategies”

Main, paragraph 2Find in source

“None had any data on women who were HIV positive.”

Discussion ¶4Find in source

Randomization method (random function in Excel) and unit (participant) are described. Blinding of participants and treating nurses was not feasible, but outcome assessors were blinded. Sample size was calculated with explicit assumptions. Inclusion/exclusion criteria are detailed. Outlier handling is addressed via multiple imputation for missing data. Controls are inherent in the comparator arms. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial design is rigorous with adequate randomization, blinding of outcome assessors, sample size estimation, and pre-specified inclusion/exclusion criteria.

Evidence

“Before the study was launched, a randomization list was generated by the IARC data manager using the random function in Excel to allocate a treatment to each participant’s ID.”

MethodsFind in source

paraphrase[Methods, Study design]

“The prospective, randomized, three-arm, partially blind, noninferiority trial... was launched in August 2017”

paraphrase[Methods, Sample size estimation]

“We used the following assumptions: the treatment success rate in the cryotherapy (comparator) arm to be 55%... a noninferiority margin of 4%; an annual follow-up default rate of 30%; an 80% power; and a 2.5% significance level.”

PASSReviewer 2· 90% conf

The trial design is rigorous with adequate randomization, blinding of outcome assessors, sample size estimation, and prespecified inclusion/exclusion criteria.

Evidence

“a randomization list was generated by the IARC data manager using the random function in Excel to allocate a treatment to each participant’s ID.”

MethodsFind in source

“We initiated a prospective, randomized, outcome assessor-blind, noninferiority trial”

Main, paragraph 3Find in source

“We estimated that a total sample size of 3,123 women who were VIA screen-positive would be required”

MethodsFind in source

Sex is reported (all female). Age, HIV status, HPV status, and other reproductive factors are detailed in Table 1. Demographics are adequate. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics, including age, HIV status, and HPV status, are comprehensively reported.

Evidence

“Of the 3,124 women recruited, 38.5% ( n = 1,203) were aged 25 to 29, 39.8% ( n = 1,244) were aged 30 to 39, 18.8% ( n = 587) were aged 40 to 49 and 2.9% ( n = 90) were aged 50 to 59 years”

ResultsFind in source

“HIV status was known for 3,071 (98.3%) participants, 58.6% ( n = 1,801) being HIV positive.”

ResultsFind in source

“Overall, 53.7% ( n = 1,621) of the 3,016 participants with a valid HPV report were positive”

ResultsFind in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics, including age, HIV status, and HPV status, are comprehensively reported.

Evidence

“Of the 3,124 women recruited, 38.5% ( n = 1,203) were aged 25 to 29, 39.8% ( n = 1,244) were aged 30 to 39, 18.8% ( n = 587) were aged 40 to 49 and 2.9% ( n = 90) were aged 50 to 59 years”

ResultsFind in source

“HIV status was known for 3,071 (98.3%) participants, 58.6% ( n = 1,801) being HIV positive.”

ResultsFind in source

“Table 1 Baseline sociodemographic characteristics, reproductive health history and clinical details”

Table 1Find in source

The study was approved by the IARC and UNC research ethics committees with protocol numbers. Written informed consent was obtained from each participant. Regulatory compliance is implied through adherence to good clinical practice.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from named committees and informed consent are clearly documented.

Evidence

“The study was reviewed and approved by the research ethics committees at IARC (IEC 2016-01 approved on 4 March 2016) and UNC (MH/101/23/10/1 approved on 10 July 2017).”

EthicsFind in source

“Each study participant signed a written informed consent.”

EthicsFind in source

“To ensure the safety and well-being of the trial participants, all study staff were trained in good clinical practice.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval from named committees and informed consent are clearly documented.

Evidence

“The study was reviewed and approved by the research ethics committees at IARC (IEC 2016-01 approved on 4 March 2016) and UNC (MH/101/23/10/1 approved on 10 July 2017).”

EthicsFind in source

“Each study participant signed a written informed consent.”

EthicsFind in source

“all study staff were trained in good clinical practice.”

MethodsFind in source

The thermal ablation device (Liger Medical) and the Xpert HPV test (Cepheid) are identified with manufacturer. The device's specifications are described. Statistical software (STATA v.17.0) is identified. No antibodies, cell lines, or mycoplasma testing are applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational device and HPV test are adequately identified, and statistical software is named.

Evidence

“A Liger TA device was used to perform TA.”

MethodsFind in source

“All cervical samples were analyzed using the Xpert HPV test (Cepheid)”

MethodsFind in source

“analyzed using STATA v.17.0 (Stata-Corp)”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational device and HPV test are adequately identified; other bench resources are not applicable.

Evidence

“A Liger TA device was used to perform TA.”

MethodsFind in source

“All cervical samples were analyzed using the Xpert HPV test (Cepheid)”

MethodsFind in source

“analyzed using STATA v.17.0 (Stata-Corp).”

Statistical analysisFind in source

Tests are named (Pearson chi-squared, generalized linear models). Assumptions are handled via multiple imputation and clustering. Exact p-values are reported (e.g., P = 0.83). Effect sizes with 95% CIs are provided. Software is identified. Data presentation includes per-group n and CIs. Mathematical plausibility checks were not possible for all values, but no inconsistencies were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

“the comparison between the three study arms was determined using the Pearson chi-squared test.”

Statistical analysisFind in source

“The lower bounds of the 95% confidence intervals (CIs) of risk ratios for both TA and cryotherapy (0.97–1.08) and TA versus LLETZ (0.95–1.05) were above 0.61”

ResultsFind in source

“thus demonstrating noninferiority ( P = 0.83)”

AbstractFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

“the comparison between the three study arms was determined using the Pearson chi-squared test.”

Statistical analysisFind in source

paraphrase[Table 2]

“Risk ratio for TA versus cryotherapy (95% CI) b 1.03 (0.97–1.08)”

“demonstrating noninferiority ( P = 0.83).”

AbstractFind in source

The data availability statement describes a request-based process with a data transfer agreement but does not name a repository or platform. Code availability is similarly request-based via email. No accession numbers or repository deposits are provided. For a clinical trial, managed access is acceptable, but the mechanism is not fully concrete.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data and code availability statements are present but vague, lacking a concrete repository or managed-access platform.

Evidence

“External researchers can make written requests for data sharing before publication or presentation. Requests will be assessed on a case-by-case basis in consultation with the lead and coinvestigators.”

Data availabilityFind in source

“External researchers can make written requests for the code used in the statistical analysis from R. Muwonge (muwonger@iarc.who.int).”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data and code availability statements are present but vague, lacking a concrete repository or managed-access platform.

Evidence

“External researchers can make written requests for data sharing before publication or presentation. Requests will be assessed on a case-by-case basis”

Data availabilityFind in source

“External researchers can make written requests for the code used in the statistical analysis from R. Muwonge”

Data availabilityFind in source

Methods are detailed. Trial registration is provided (NCT02956239). A reporting summary is mentioned. All outcomes are reported, including negative results. Limitations are discussed extensively. Conclusions are proportional to the evidence. Funding and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with complete methods, trial registration, limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov registration: NCT02956239”

AbstractFind in source

paraphrase[Discussion, paragraph 5]

“However, our RCT has limitations. First, given the challenges of performing quality-assured histopathology in Zambia, we decided to adopt a pragmatic approach...”

“The study is fully funded by the US National Institutes of Health (NIH) (no. 1UH2CA202721-01).”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent, with detailed methods, trial registration, discussion of limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov registration: NCT02956239”

AbstractFind in source

paraphrase[Discussion, paragraph 6]

“However, our RCT has limitations. First, given the challenges of performing quality-assured histopathology in Zambia...”

“The study is fully funded by the US National Institutes of Health (NIH) (no. 1UH2CA202721-01).”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 24 references by DOI: 18 verified — 6 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

9 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 9 minor suggestions below.

9 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally trustworthy, but an informed reader should weigh the vague data/code availability and the Table 5 inconsistencies. A correction or erratum is warranted to fix the Table 5 point estimates and to provide a more concrete data-sharing mechanism; otherwise, the conclusions are supported by the reported evidence.

1.
HIGHcopyedit
Correct the point estimates in Table 5 (Extended phase) so they fall within the reported 95% CIs (e.g., 69.0% should likely be 78.4% for CI 74.7–82.0; similarly for 68.7%, 64.1%, 67.2%).
The current point estimates are internally inconsistent with the confidence intervals, which undermines the credibility of the reported results and could mislead readers.
2.
HIGHdata code
Replace the vague data availability statement with a concrete mechanism, such as naming a managed-access repository (e.g., Vivli) or a data access committee with a defined process and timeframe.
A request-based statement without a platform or timeline is not auditable and fails to meet transparency expectations for a clinical trial.
3.
HIGHdata code
Deposit the statistical analysis code in a public repository (e.g., Zenodo or GitHub) with a DOI and provide the link in the Code Availability section.
Email-based code sharing is not reproducible; a public repository with a persistent identifier enables independent verification.
4.
MEDIUMcopyedit
Fix the duplicate word 'were' in Discussion, paragraph 2 ('were were VIA positive' → 'were VIA positive').
Typographical errors detract from the manuscript's professionalism and readability.
5.
MEDIUMreporting
Clarify the derivation of the noninferiority margin (4%) in the Methods, citing the rationale or source.
The noninferiority margin is a critical design parameter; its derivation should be transparent for reproducibility.
6.
MEDIUMreporting
Report the exact number of participants with missing data for each outcome and describe the multiple imputation model details (variables, number of imputations).
Transparent handling of missing data is essential for assessing potential bias in the results.
7.
MEDIUMreporting
Add an explicit statement in the reporting summary that the trial followed CONSORT guidelines.
Explicit adherence to CONSORT enhances the credibility of the reporting and facilitates readers' assessment.
8.
LOWdata code
Consider providing a de-identified dataset in a repository if ethically permissible, or at least specify the data transfer agreement terms and expected timeline for decisions.
A more concrete data-sharing plan would improve transparency and allow independent re-analysis.
9.
LOWother
Specify the version of the Xpert HPV test used and any relevant lot numbers for the thermal ablation device.
Providing specific product versions and lot numbers enhances reproducibility and allows readers to assess potential batch effects.

Full text (66,483 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.

Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, Chisele S, Shibemba AL, Sauvaget C, Sankaranarayanan R, Prendiville W, Parham GP

Read full text (PMC)

DOI

10.1038/s41591-024-03080-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0e7f1368-4384-435f-83d7-3d25617699f4" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0e7f1368-4384-435f-83d7-3d25617699f4/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a55430236b9b276b858a3e50dbe39504e035af98ed4fe16eb37bdd9fae1aabf2

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is treatment success defined as type-specific HPV clearance or negative VIA, which are surrogate markers for cervical precancer resolution. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD) and does not cite validated evidence linking these surrogates to clinical outcomes such as prevention of cervical cancer. Although the discussion mentions HPV clearance as a 'test of cure' with high negative predictive value, this is not a validated surrogate for the clinical outcome of cervical cancer prevention.
“The primary outcome was treatment success, defined as either type-specific HPV clearance at the follow-up in participants positive for HPV at baseline, or a negative visual inspection with acetic acid test for those who had a negative HPV test at baseline.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The treatment success rates are around 71-74% overall, and among HPV-positive women, type-specific clearance is only about 50%. These are not anchored to a minimal clinically important difference or to the clinical significance for preventing cervical cancer. The paper does not provide a benchmark for what constitutes a clinically meaningful success rate, and the rates are lower than those reported in meta-analyses using histopathological endpoints.
“After a median follow-up of 12 months, treatment success rates were 74.0%, 71.1% and 71.4% for the TA, cryotherapy and LLETZ arms, respectively, thus demonstrating noninferiority ( P = 0.83).”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit9 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise, citing prior work and guidelines, and provides a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 3]

paraphrase[Discussion, paragraph 4]

PASSReviewer 2· 90% conf

The study clearly establishes the scientific premise, citing prior work and guidelines, and provides a logical rationale for the trial.

Evidence

paraphrase[Main, paragraph 1]

Main, paragraph 2Find in source

“None had any data on women who were HIV positive.”

Discussion ¶4Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial design is rigorous with adequate randomization, blinding of outcome assessors, sample size estimation, and pre-specified inclusion/exclusion criteria.

Evidence

“Before the study was launched, a randomization list was generated by the IARC data manager using the random function in Excel to allocate a treatment to each participant’s ID.”

MethodsFind in source

paraphrase[Methods, Study design]

“The prospective, randomized, three-arm, partially blind, noninferiority trial... was launched in August 2017”

paraphrase[Methods, Sample size estimation]

PASSReviewer 2· 90% conf

The trial design is rigorous with adequate randomization, blinding of outcome assessors, sample size estimation, and prespecified inclusion/exclusion criteria.

Evidence

“a randomization list was generated by the IARC data manager using the random function in Excel to allocate a treatment to each participant’s ID.”

MethodsFind in source

“We initiated a prospective, randomized, outcome assessor-blind, noninferiority trial”

Main, paragraph 3Find in source

“We estimated that a total sample size of 3,123 women who were VIA screen-positive would be required”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics, including age, HIV status, and HPV status, are comprehensively reported.

Evidence

“Of the 3,124 women recruited, 38.5% ( n = 1,203) were aged 25 to 29, 39.8% ( n = 1,244) were aged 30 to 39, 18.8% ( n = 587) were aged 40 to 49 and 2.9% ( n = 90) were aged 50 to 59 years”

ResultsFind in source

“HIV status was known for 3,071 (98.3%) participants, 58.6% ( n = 1,801) being HIV positive.”

ResultsFind in source

“Overall, 53.7% ( n = 1,621) of the 3,016 participants with a valid HPV report were positive”

ResultsFind in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics, including age, HIV status, and HPV status, are comprehensively reported.

Evidence

“Of the 3,124 women recruited, 38.5% ( n = 1,203) were aged 25 to 29, 39.8% ( n = 1,244) were aged 30 to 39, 18.8% ( n = 587) were aged 40 to 49 and 2.9% ( n = 90) were aged 50 to 59 years”

ResultsFind in source

“HIV status was known for 3,071 (98.3%) participants, 58.6% ( n = 1,801) being HIV positive.”

ResultsFind in source

“Table 1 Baseline sociodemographic characteristics, reproductive health history and clinical details”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from named committees and informed consent are clearly documented.

Evidence

“The study was reviewed and approved by the research ethics committees at IARC (IEC 2016-01 approved on 4 March 2016) and UNC (MH/101/23/10/1 approved on 10 July 2017).”

EthicsFind in source

“Each study participant signed a written informed consent.”

EthicsFind in source

“To ensure the safety and well-being of the trial participants, all study staff were trained in good clinical practice.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval from named committees and informed consent are clearly documented.

Evidence

“The study was reviewed and approved by the research ethics committees at IARC (IEC 2016-01 approved on 4 March 2016) and UNC (MH/101/23/10/1 approved on 10 July 2017).”

EthicsFind in source

“Each study participant signed a written informed consent.”

EthicsFind in source

“all study staff were trained in good clinical practice.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational device and HPV test are adequately identified, and statistical software is named.

Evidence

“A Liger TA device was used to perform TA.”

MethodsFind in source

“All cervical samples were analyzed using the Xpert HPV test (Cepheid)”

MethodsFind in source

“analyzed using STATA v.17.0 (Stata-Corp)”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational device and HPV test are adequately identified; other bench resources are not applicable.

Evidence

“A Liger TA device was used to perform TA.”

MethodsFind in source

“All cervical samples were analyzed using the Xpert HPV test (Cepheid)”

MethodsFind in source

“analyzed using STATA v.17.0 (Stata-Corp).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

“the comparison between the three study arms was determined using the Pearson chi-squared test.”

Statistical analysisFind in source

“The lower bounds of the 95% confidence intervals (CIs) of risk ratios for both TA and cryotherapy (0.97–1.08) and TA versus LLETZ (0.95–1.05) were above 0.61”

ResultsFind in source

“thus demonstrating noninferiority ( P = 0.83)”

AbstractFind in source

PASSReviewer 2· 85% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are exact where reported.

Evidence

“the comparison between the three study arms was determined using the Pearson chi-squared test.”

Statistical analysisFind in source

paraphrase[Table 2]

“Risk ratio for TA versus cryotherapy (95% CI) b 1.03 (0.97–1.08)”

“demonstrating noninferiority ( P = 0.83).”

AbstractFind in source

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Data and code availability statements are present but vague, lacking a concrete repository or managed-access platform.

Evidence

Data availabilityFind in source

“External researchers can make written requests for the code used in the statistical analysis from R. Muwonge (muwonger@iarc.who.int).”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data and code availability statements are present but vague, lacking a concrete repository or managed-access platform.

Evidence

“External researchers can make written requests for data sharing before publication or presentation. Requests will be assessed on a case-by-case basis”

Data availabilityFind in source

“External researchers can make written requests for the code used in the statistical analysis from R. Muwonge”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with complete methods, trial registration, limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov registration: NCT02956239”

AbstractFind in source

paraphrase[Discussion, paragraph 5]

“However, our RCT has limitations. First, given the challenges of performing quality-assured histopathology in Zambia, we decided to adopt a pragmatic approach...”

“The study is fully funded by the US National Institutes of Health (NIH) (no. 1UH2CA202721-01).”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent, with detailed methods, trial registration, discussion of limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov registration: NCT02956239”

AbstractFind in source

paraphrase[Discussion, paragraph 6]

“However, our RCT has limitations. First, given the challenges of performing quality-assured histopathology in Zambia...”

“The study is fully funded by the US National Institutes of Health (NIH) (no. 1UH2CA202721-01).”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 24 references by DOI: 18 verified — 6 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

9 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 9 minor suggestions below.

9 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHcopyedit
Correct the point estimates in Table 5 (Extended phase) so they fall within the reported 95% CIs (e.g., 69.0% should likely be 78.4% for CI 74.7–82.0; similarly for 68.7%, 64.1%, 67.2%).
The current point estimates are internally inconsistent with the confidence intervals, which undermines the credibility of the reported results and could mislead readers.
2.
HIGHdata code
Replace the vague data availability statement with a concrete mechanism, such as naming a managed-access repository (e.g., Vivli) or a data access committee with a defined process and timeframe.
A request-based statement without a platform or timeline is not auditable and fails to meet transparency expectations for a clinical trial.
3.
HIGHdata code
Deposit the statistical analysis code in a public repository (e.g., Zenodo or GitHub) with a DOI and provide the link in the Code Availability section.
Email-based code sharing is not reproducible; a public repository with a persistent identifier enables independent verification.
4.
MEDIUMcopyedit
Fix the duplicate word 'were' in Discussion, paragraph 2 ('were were VIA positive' → 'were VIA positive').
Typographical errors detract from the manuscript's professionalism and readability.
5.
MEDIUMreporting
Clarify the derivation of the noninferiority margin (4%) in the Methods, citing the rationale or source.
The noninferiority margin is a critical design parameter; its derivation should be transparent for reproducibility.
6.
MEDIUMreporting
Report the exact number of participants with missing data for each outcome and describe the multiple imputation model details (variables, number of imputations).
Transparent handling of missing data is essential for assessing potential bias in the results.
7.
MEDIUMreporting
Add an explicit statement in the reporting summary that the trial followed CONSORT guidelines.
Explicit adherence to CONSORT enhances the credibility of the reporting and facilitates readers' assessment.
8.
LOWdata code
Consider providing a de-identified dataset in a repository if ethically permissible, or at least specify the data transfer agreement terms and expected timeline for decisions.
A more concrete data-sharing plan would improve transparency and allow independent re-analysis.
9.
LOWother
Specify the version of the Xpert HPV test used and any relevant lot numbers for the thermal ablation device.
Providing specific product versions and lot numbers enhances reproducibility and allows readers to assess potential batch effects.

Full text (66,483 chars)Analyzed: Aug 16, 2026